Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Treat Stroke to Target Trial

58 views

Published on

La Dra. Susana del Prado Díaz analiza los resultados del estudio publicado en AHA Scientific Sessions 2019.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Treat Stroke to Target Trial

  1. 1. Treat Stroke to Target Trial Susana del Prado D�az
  2. 2. Treat Stroke to Target Trial Susana del Prado D�az
  3. 3. Treat Stroke to Target Trial Susana del Prado D�az
  4. 4. Treat Stroke to Target Trial Susana del Prado D�az
  5. 5. Treat Stroke to Target Trial Susana del Prado D�az
  6. 6. Treat Stroke to Target Trial Susana del Prado D�az
  7. 7. Treat Stroke to Target Trial Susana del Prado D�az Estatina sola: 94% Estatina + Ezetimibe: 5% Estatina sola: 66% Estatina + Ezetimibe: 33%
  8. 8. Treat Stroke to Target Trial Susana del Prado D�az RESULTADOS PRE SPECIFIED COVARIANTES ADJUSTMENTS - Age - Sex - Entry event (ischemic stroke vs TIA) - Time from symptom onset to randomization - Geographical regi�n (France vs Korea) (SPARCL trial adjustment) 22% RRR Adjusted HR = 0.78 [95% CI 0.61 to 0.98; P value = 0.036] END POINT PRIMARIO Compuesto de: - Ictus no fatal - IAM no fatal - AI que requiera revascularizaci�n urgente - AIT seguido de revascularizaci�n carotidea urgente - Muerte vascular incluida muerte s�bita
  9. 9. Treat Stroke to Target Trial Susana del Prado D�az ENDPOINTS SECUNDARIOS
  10. 10. Treat Stroke to Target Trial Susana del Prado D�az

×